RAP-219 clinical trials
Also written RAP-219.
How each study uses RAP-219 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RAP-219 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RAP-219
- 5
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Rapport Therapeutics Inc. (5)
Studies
Open first, then newest update. How each study uses RAP-219 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresRecruitingPhase 3Rapport Therapeutics Inc.NCT07594119Written as RAP-219
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1RecruitingPhase 3Rapport Therapeutics Inc.NCT07563881Written as RAP-219
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresRecruitingPhase 2Rapport Therapeutics Inc.NCT07219407Written as RAP-219
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderCompletedPhase 2Rapport Therapeutics Inc.NCT07046494Written as RAP-219
- Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyCompletedPhase 2Rapport Therapeutics Inc.NCT06377930Written as RAP-219